^
    Back
    Association details:
    Biomarker:HRD
    Cancer:Ovarian Cancer
    Drug:ABT-767 (PARP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2018
    Title:

    53BP1 as a predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.

    Published date:
    05/16/2018
    Excerpt:
    Responses to the PARPi ABT-767 were observed exclusively in ovarian cancers with an HR-deficiency….Differences in complementary repair pathways, particularly in the NHEJ pathway, correlate with PARPi response of HR-deficient ovarian carcinomas.
    DOI:
    10.1200/JCO.2018.36.15_suppl.5538